Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

被引：9

作者：

Guo, Xiaojin ^{[1
]}

Du, He ^{[2
]}

Li, Jiayu ^{[2
]}

Yang, Menghang ^{[2
]}

Xiong, Anweng ^{[2
]}

Zhang, Haiping ^{[2
]}

Wu, Fengying ^{[2
]}

机构：

[1] Hebei Med Univ, Hosp 4, Dept Immunooncol, Shijiazhuang 050011, Hebei, Peoples R China

[2] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, 507 Zhengmin Rd, Shanghai 200000, Peoples R China

来源：

CANCER DRUG RESISTANCE | 2022年 / 5卷 / 01期

关键词：

Non-squamous NSCLC; driver mutations; immune checkpoint inhibitor; CHECKPOINT INHIBITORS; ADVANCED NSCLC; OPEN-LABEL; MUTATIONS; IMMUNOTHERAPY; BLOCKADE; SURVIVAL; SAFETY; HER2;

D O I：

10.20517/cdr.2021.85

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: The objective of our study was to assess the efficacy of immune checkpoint inhibitors (ICIs) on patients with non-small-cell lung cancer (NSCLC) harboring oncogenic alterations. Methods: We retrospectively enrolled patients with advanced non-squamous NSCLC who were treated with antiPD-1-based monotherapy or combined immunotherapy. Major characteristics including PD- L1 expression, treatment, and survival were analyzed. Results: In total, 309 non-squamous NSCLC patients with a median age of 61 years (range 20-88 years) including 70.9% male were retrospectively enrolled. The molecular alterations involved epidermal growth factor receptor (EGFR) (n = 81), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (n = 31), anaplastic lymphoma kinase (ALK) (n = 1), human epidermal growth factor receptor 2 (HER2) (n = 12), V-raf murine sarcoma viral oncogene homolog (BRAF) (n = 2), rearranged during transfection (n = 4), and c-ros oncogene 1 (ROS1) (n = 3). In the EGFR subset, the ORR was 30.9% (n = 81) and PFS was significantly shorter than WT group (median PFS: 5.7 months vs. 7.1 months; P = 0.0061). In subgroup analyses, ICI combined therapy was significantly correlated with a longer PFS compared with ICI monotherapy (median PFS: 7.7 months vs. 4.7 months; P = 0.0112). In KRAS patients, ORR was 51.6% (n = 31). No significant difference was found in subgroup analyses. The ORR and PFS were 16.7% (n = 12) and 28.6% (n = 7), 7.8 months and 9.0 months for HER2 and EGFR Exon20 insertion patients, respectively. Three ROS1 patients were enrolled with a PFS of 16.0, 34.2, and 45.0 months individually, and one ALK patient with PFS of 4.4 months was identified. No response was found in two BRAF patients. Conclusion: ICI-based combination therapy can bring benefit to patients with EGFR-mutant NSCLC. ICI-based combination therapy could be considered for patients with ROS1 rearrangement, HER2 mutation and EGFR Exon20 insertion NSCLC.

引用

页码：15 / 24

页数：10

共 28 条

[1] Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions [J].

Ackermann, Christoph Jakob ;

Stock, Gustavo ;

Tay, Rebecca ;

Dawod, Mohammed ;

Gomes, Fabio ;

Califano, Raffaele .

ONCOTARGETS AND THERAPY, 2019, 12 :7857-7864

[2] TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma [J].

Biton, Jerome ;

Mansuet-Lupo, Audrey ;

Pecuchet, Nicolas ;

Alifano, Marco ;

Ouakrim, Hanane ;

Arrondeau, Jennifer ;

Boudou-Rouquette, Pascaline ;

Goldwasser, Francois ;

Leroy, Karen ;

Goc, Jeremy ;

Wislez, Marie ;

Germain, Claire ;

Laurent-Puig, Pierre ;

Dieu-Nosjean, Marie-Caroline ;

Cremer, Isabelle ;

Herbst, Ronald ;

Blons, Helene ;

Damotte, Diane .

CLINICAL CANCER RESEARCH, 2018, 24 (22) :5710-5723

[3] The great escape: tumour cell plasticity in resistance to targeted therapy [J].

Boumahdi, Soufiane ;

de Sauvage, Frederic J. .

NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (01) :39-56

[4] Comprehensive molecular profiling of lung adenocarcinoma [J].

Collisson, Eric A. ;

Campbell, Joshua D. ;

Brooks, Angela N. ;

Berger, Alice H. ;

Lee, William ;

Chmielecki, Juliann ;

Beer, David G. ;

Cope, Leslie ;

Creighton, Chad J. ;

Danilova, Ludmila ;

Ding, Li ;

Getz, Gad ;

Hammerman, Peter S. ;

Hayes, D. Neil ;

Hernandez, Bryan ;

Herman, James G. ;

Heymach, John V. ;

Jurisica, Igor ;

Kucherlapati, Raju ;

Kwiatkowski, David ;

Ladanyi, Marc ;

Robertson, Gordon ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Sinha, Rileen ;

Sougnez, Carrie ;

Tsao, Ming-Sound ;

Travis, William D. ;

Weinstein, John N. ;

Wigle, Dennis A. ;

Wilkerson, Matthew D. ;

Chu, Andy ;

Cherniack, Andrew D. ;

Hadjipanayis, Angela ;

Rosenberg, Mara ;

Weisenberger, Daniel J. ;

Laird, Peter W. ;

Radenbaugh, Amie ;

Ma, Singer ;

Stuart, Joshua M. ;

Byers, Lauren Averett ;

Baylin, Stephen B. ;

Govindan, Ramaswamy ;

Meyerson, Matthew ;

Rosenberg, Mara ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Kim, Jaegil ;

Stewart, Chip .

NATURE, 2014, 511 (7511) :543-550

[5] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma [J].

Dong, Zhong-Yi ;

Zhong, Wen-Zhao ;

Zhang, Xu-Chao ;

Su, Jian ;

Xie, Zhi ;

Liu, Si-Yang ;

Tu, Hai-Yan ;

Chen, Hua-Jun ;

Sun, Yue-Li ;

Zhou, Qing ;

Yang, Jin-Ji ;

Yang, Xue-Ning ;

Lin, Jia-Xin ;

Yan, Hong-Hong ;

Zhai, Hao-Ran ;

Yan, Li-Xu ;

Liao, Ri-Qiang ;

Wu, Si-Pei ;

Wu, Yi-Long .

CLINICAL CANCER RESEARCH, 2017, 23 (12) :3012-3024

[6] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer [J].

Drilon, A. ;

Oxnard, G. R. ;

Tan, D. S. W. ;

Loong, H. H. F. ;

Johnson, M. ;

Gainor, J. ;

McCoach, C. E. ;

Gautschi, O. ;

Besse, B. ;

Cho, B. C. ;

Peled, N. ;

Weiss, J. ;

Kim, Y. -J. ;

Ohe, Y. ;

Nishio, M. ;

Park, K. ;

Patel, J. ;

Seto, T. ;

Sakamoto, T. ;

Rosen, E. ;

Shah, M. H. ;

Barlesi, F. ;

Cassier, P. A. ;

Bazhenova, L. ;

De Braud, F. ;

Garralda, E. ;

Velcheti, V. ;

Satouchi, M. ;

Ohashi, K. ;

Pennell, N. A. ;

Reckamp, K. L. ;

Dy, G. K. ;

Wolf, J. ;

Solomon, B. ;

Falchook, G. ;

Ebata, K. ;

Nguyen, M. ;

Nair, B. ;

Zhu, E. Y. ;

Yang, L. ;

Huang, X. ;

Olek, E. ;

Rothenberg, S. M. ;

Goto, K. ;

Subbiah, V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09) :813-824

[7] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[8] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[9] Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study [J].

Garassino, Marina Chiara ;

Cho, Byoung-Chul ;

Kim, Joo-Hang ;

Mazieres, Julien ;

Vansteenkiste, Johan ;

Lena, Herve ;

Jaime, Jesus Corral ;

Gray, Jhanelle E. ;

Powderly, John ;

Chouaid, Christos ;

Bidoli, Paolo ;

Wheatley-Price, Paul ;

Park, Keunchil ;

Soo, Ross A. ;

Poole, Lynne ;

Wadsworth, Catherine ;

Dennis, Phillip A. ;

Rizvi, Naiyer A. .

LUNG CANCER, 2020, 147 :137-142

[10] Treating KRAS-mutant NSCLC: latest evidence and clinical consequences [J].

Garrido, Pilar ;

Eugenia Olmedo, Maria ;

Gomez, Ana ;

Paz Ares, Luis ;

Lopez-Rios, Fernando ;

Manuel Rosa-Rosa, Juan ;

Palacios, Jose .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (09) :589-597

← 1 2 3 →